Tixagevimab‐Cilgavimab: Utilization in the solid organ transplant population

Shaikh, Suhail; Morado, Faiza; Kawewat-Ho, Pnada; Cartus, Rachel; Davoudi, Roland; Forrester, Kevin; Azizian, Krist; Blodget, Emily; Maw, Thin Thin; Nanda, Neha

doi:10.1111/ctr.14661

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tixagevimab-cilgavimab (Evusheld ® ) is a long-acting dual monoclonal antibody against the SARS-CoV-2 spike protein, which has been available for pre-exposure prophylaxis (PrEP)-in adjunction to vaccination -in severely immunocompromised patients in Belgium since May 2022, as it retained activity against some circulating SARS-CoV-2 Omicron variants. Emerging international evidence of prophylactic treatment with tixagevimab-cilgavimab suggest efficacy for COVID-19 related complications in SOT recipients, but data in LTx recipients are scarce [10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis

Demolder,

Schaevers,

Lagrou

et al. 2024

Transpl Int

View full text Add to dashboard Cite

Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after PrEP in a retrospective single-center study, including 264 LTx recipients who received PrEP between June 2022 and December 2022, when Omicron BA.5 was the dominant circulating SARS-CoV-2 variant. PrEP was indicated for fully vaccinated patients with poor seroconversion (anti-S <260 BAU/mL). COVID-19 breakthrough infection after PrEP occurred in 11.0% within the first 3 months, increasing to 17.4% within 6 months. Hospitalization rate rose from 27.6% to 52.9% (p = 0.046), while ICU admissions and COVID-19 mortality remained low, respectively occurring in 6.5% and 4.3% of patients with breakthrough infection within 6 months. COVID-19 breakthrough infection and associated hospitalization remained an important problem during the Omicron BA.5 surge in fully vaccinated LTx recipients with deficient seroconversion, despite PrEP with tixagevimab-cilgavimab. However, ICU admissions and COVID-19 mortality were low. Waning of neutralizing effects of PrEP and changing circulating SARS-CoV-2 variants may explain increases in COVID-19 infections and hospitalizations over time after PrEP, highlighting the need for novel, long-term effective PrEP strategies in these high-risk patients.

show abstract